EP0236429B1 - Systeme de synthese de la biotine - Google Patents
Systeme de synthese de la biotine Download PDFInfo
- Publication number
- EP0236429B1 EP0236429B1 EP86905574A EP86905574A EP0236429B1 EP 0236429 B1 EP0236429 B1 EP 0236429B1 EP 86905574 A EP86905574 A EP 86905574A EP 86905574 A EP86905574 A EP 86905574A EP 0236429 B1 EP0236429 B1 EP 0236429B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- biotin
- bio
- bir
- plasmid
- plasmid dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims abstract description 206
- 235000020958 biotin Nutrition 0.000 title claims abstract description 101
- 239000011616 biotin Substances 0.000 title claims abstract description 101
- 229960002685 biotin Drugs 0.000 title claims abstract description 101
- 230000015572 biosynthetic process Effects 0.000 title description 5
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 239000013612 plasmid Substances 0.000 claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 244000005700 microbiome Species 0.000 claims description 16
- 101150029327 bioB gene Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 3
- 108700040198 Biotin synthases Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 abstract description 11
- 238000010276 construction Methods 0.000 abstract description 10
- 230000014759 maintenance of location Effects 0.000 abstract description 8
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- 108091008053 gene clusters Proteins 0.000 abstract 1
- 101150031021 birA gene Proteins 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 239000012634 fragment Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 15
- 101100494110 Escherichia coli (strain K12) birA gene Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 101150023452 bioD gene Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000004098 Tetracycline Substances 0.000 description 8
- 101150076754 bioA gene Proteins 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- 235000019364 tetracycline Nutrition 0.000 description 8
- 150000003522 tetracyclines Chemical class 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 101100381793 Bacillus subtilis (strain 168) bioK gene Proteins 0.000 description 5
- 101100218845 Escherichia coli (strain K12) bioH gene Proteins 0.000 description 5
- 101150085692 bioC gene Proteins 0.000 description 5
- 101150032820 bioF gene Proteins 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101150060445 uvrB gene Proteins 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 101150043536 bioH gene Proteins 0.000 description 3
- 229940068840 d-biotin Drugs 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000012145 high-salt buffer Substances 0.000 description 2
- 108010025649 holocarboxylase synthetases Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
- 229960002064 kanamycin sulfate Drugs 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RUKJCCIJLIMGEP-ONEGZZNKSA-N 4-dimethylaminocinnamaldehyde Chemical compound CN(C)C1=CC=C(\C=C\C=O)C=C1 RUKJCCIJLIMGEP-ONEGZZNKSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 108010032108 biotin repressor Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003167 genetic complementation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003032 human food additive Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/185—Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system
- C12P17/186—Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system containing a 2-oxo-thieno[3,4-d]imidazol nucleus, e.g. Biotin
Definitions
- the present invention relates in general to systems for the microbial production of biotin and in particular to systems wherein at least a part of the biotin operon is present on a plasmid within a biotin retention-deficient mutant host cell.
- Biotin also known as vitamin H, is probably an essential component of all cells. Some microorganisms, including baker's yeast, and all animals (except the protozoan Tetrahymena) are unable to synthesize biotin effectively and must therefore obtain biotin from their environment in order to survive.
- biotin is very expensive to manufacture by presently available, chemical synthetic methods.
- beet molasses containing 0.015-0.15 ⁇ grams of biotin per gram
- other natural sources of biotin may be used to supplement synthetic biotin, there exists a need for other sources.
- a system for the production of biotin comprising: a microorganism having a bir A ⁇ genotype and plasmid DNA, within said cell, encoding at least one gene product of the biotin operon or a functional homolog thereof.
- Another aspect of the present invention comprises a system for the production of biotin comprising: a microorganism having a ( bio ⁇ , bir A ⁇ , bio R ⁇ ) genotype: and plasmid DNA, within said cell, wherein said plasmid DNA encodes the biotin operon and wherein said plasmid DNA is uvr B ⁇ .
- the present invention further relates to a system for the production of biotin comprising: a microorganism having a ( bio ⁇ , bir A ts , bio R ⁇ ) genotype; and plasmid DNA encodes the biotin operon and wherein said plasmid DNA is uvr B ⁇ .
- biotin which comprises transforming a microorganism having a bir A ⁇ genotype with a plasmid DNA encoding a gene product of the biotin operon or a functional homolog thereof.
- a method of converting desthiobiotin to biotin comprising the steps of: culturing a host microorganism, having a biotin retention-deficient mutant genotype and having plasmid DNA encoding a bio B gene product of the biotin operon or a functional homolog thereof, in a medium containing desthiobiotin.
- biotin retention-deficient mutant genotype refers to a lesion in bir A gene, that produces a change in the bir A gene resulting in a decrease in the activity of the bir A gene product, that is, a mutation at the bir A locus giving rise to a diminished capacity for adenylation of biotin and is hereinafter referred to as bir A ⁇ .
- a class of preferred lesions in bir A comprise lesions which will render the activity of the enzyme dependant on temperature, that is a temperature sensitive bir A gene ( bir A TS ). Such bir A TS mutants decrease the bir A function as the temperature of the system increases.
- Preferred host cells include biotin-requiring strains (genotype: bio ⁇ ) strains deficient in the repressor of the biotin operon (genotype: bio R ⁇ ) and biotin-requiring strains deficient in the repressor function (genotype: bio ⁇ , bio R ⁇ ).
- the most preferred host cells are bio R ⁇ strains.
- the term "functional homolog of a gene product of the biotin operon” refers to a polypeptide which has the same function as, but which may have the same amino acid sequence as or different in amino acid sequence from, the gene product.
- Such functional homologs include, for example, polypeptide products of allelic variations of the genes of the biotin operon; analogs and fragments of these polypeptides; and synthetic polypeptides which may be dissimilar in primary structure (amino acid sequence) but which share secondary structures that allow them to possess biological and immunological activities of gene products of the biotin operon [Kaiser, et al., Science , 223 , 249-255 (1984)].
- FIG. 1 A flow chart of biotin biosynthesis is presented in Fig. 1.
- Six enzymes involved in biotin biosynthesis have been assigned to six genetic loci: bio A, bio B, bio C, bio D, bio F and bio H. Specific reactions catalyzed by bio A, bio B, bioD and bio F gene products have been characterized. Cofactors and substrates for each of these reactions, with the exception of a sulfur atom donor in the last enzymatic step, have been identified.
- bio C and bio H gene products have not been characterized due to limitations of crossfeeding studies (wherein biotin-deficient strains obtain survival only by utilizing biotin or by utilizing biosynthetic precursors of biotin excreted by cells with which they are co-cultured), these loci have been identified as essential by genetic complementation.
- the six genes coding for biotin synthetic enzymes are located in two regions of the E. coli chromosome. Five of the six genes ( bio A, bio B, bio C, bio D and bio F) are contained in a bidirectionally transcribed operon mapped at 17 minutes. Bio H is located at 74 minutes. The locations of the genes of the biotin operon and of two other genetic functions which impinge on the biotin biosynthetic pathway, bio R and bir A, are given in Table I. TABLE I Genetic Locus Location on E.
- biotin synthesis in E. coli is effected at the transcriptional level. After biotin is synthesized, it is adenylated by a product of a gene at a locus designated bir A , to form biotinyl-5'-adenylate as illustrated in Fig. 2.
- a biotin repressor protein, identified as a product of the bio R locus may also bind to biotinyl-5'-adenylate to increase 25-fold the affinity of the bio R gene product for a bio operator.
- Howard, et. al., Gene , 35 , 321-331, (1985) have disclosed that the bir A function and the bio R function are effected by the same protein.
- the bio operator is situated between the bio A structural gene and the bio B structural gene, as depicted in Fig. 3.
- the bio operator overlaps both the bio A gene promoter and the bio B gene promoter.
- the bio R gene product may terminate transcription by binding to the bio operator and excluding RNA polymerase from these two divergent promoters.
- Biotinyl-5'-adenylate is also a substrate for what is believed to be a third function of the bir A gene product, biotin holoenzyme synthetase.
- Biotin holoenzyme synthetase transfers biotin to acetyl-CoA carboxylase.
- Acetyl-CoA carboxylase catalyzes a critical step in fatty acid synthesis, which is essential for viability. This implies that a complete elimination of bir A activity at the initiation of the fermentation would be lethal. Therefore, at the initiation of the fermentation, it is necessary that sufficient bir A activity be present to support growth of the cells.
- Such bir A activity is readily ascertained by one of ordinary skill in the art.
- bir A activity is substantially diminished and most preferably eliminated.
- a bir A TS gene it is possible to regulate the bir A function by controlling the temperature of the fermentation system. Therefore as the temperature of the system is increased, the bir A function of the cell is decreased.
- a genetic locus which maps adjacent to the bio D locus is denominated uvr B.
- the uvr B gene has no function in biotin physiology, but acts in some way to protect E . coli cells from ultraviolet radiation as reported by Sancar, et al., Cell , 28 , 523-530 (1982).
- Three RNA molecules are transcribed from the urv B locus, one of which may interact with RNA polymerase A. Therefore, if the uvr B gene were multiplied, this interaction may be lethal for an E . coli cell. For this reason, prior to increasing the copy number of a plasmid containing a piece of DNA from the region of the E. coli chromosome which includes the biotin operon, uvr B functions should preferably be eliminated.
- a plasmid having a high copy number and most preferrably a plasmid that exhibits a moderate increase in copy number (40 to 200) upon temperature induction.
- Such plasmids are described in European Patent Application No. 136,490 and are hereinafter referred to as temperature sensitive plasmids. Therefore when utilizing such temperature sensitive plasmids, it is possible upon increasing the temperature of the reaction to moderately increase the copy number and gene dosage while maintaining cell vitality and decreasing the bir A function, thereby resulting in a system capable of producing surprisingly high yields of biotin.
- the following Examples serve to further illustrate embodiments of the present invention.
- a first plasmid designated pLC2523 (deposited August 23, 1985 as Deposit No. A.T.C.C. 53237 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland) and known to contain the biotin operon (see e.g., Sancar et al., J. Mol. Biol. , 148 , 63-76, (1981)), and a second plasmid, designated pBR322 (ATCC No. 37017) were digested with Pst I and joined by T4 DNA ligase. The mixture was then transformed, according to the procedure of Hanahan, J. Mol. Biol.
- biotin auxotrophic strain SA291 bio ⁇ , bio R+, bir A+
- SA291 bio ⁇ , bio R+, bir A+
- Colonies were selected on L agar plates containing tetracycline (12 mg/L), which killed any cells that did not contain plasmids having the tetracycline-resistance segment of pBR322.
- the selected colonies were screened for ampicillin sensitivity, an indication that a Pst I digestion fragment from pLC2523 had been inserted into the Pst I site of the ampicillin-resistance segment of pBR322, thereby rendering it incapable of conferring resistance.
- pLC2523 was cleaved with Nco I to produce a larger fragment and a smaller fragment (4.4 kilobases in length) which were separated by gel electrophoresis.
- the smaller fragment was extracted from the gel and both ends of the smaller fragment were digested with the exonuclease BAL 31.
- the plasmid pBR329 [the complete nucleotide sequence of which is published in Covarrubias, et al., Gene , 17 , 79 (1982), which is incorporated by reference herein] was digested with both Pvu II (which cleaves pBR329 in a chloramphenicol-resistance segment, to produce a blunt end) and with Pst I (which cleaves pBR329 at a site in an ampicillin-resistance segment) to obtain two pieces which were separated by gel electrophoresis.
- Pvu II which cleaves pBR329 in a chloramphenicol-resistance segment, to produce a blunt end
- Pst I which cleaves pBR329 at a site in an ampicillin-resistance segment
- the larger of the pieces (containing a tetracycline resistance segment and an origin of replication) was mixed with the four types of fragments produced by the Bgl II and Pst I digestion of the 4.4 kb Nco I fragment described above in the presence of T4 DNA ligase. As shown in Fig. 6, only those fragments containing the remainder of the bio D gene had the combination of blunt and Pst I-digested ends required to join with the larger Pvu II/ Pst I fragment from pBR329 to form a cyclic plasmid designated pBAL4.
- Bacteria of strain SA291 were transformed with the products of the ligation with the larger fragment of pBR329. Colonies were selected for tetracycline resistance, screened for ampicillin sensitivity and screened for chloramphenicol sensitivity. The lengths of the inserts in various plasmids were determined by restriction endonuclease analysis.
- the plasmids 322PstI and pBAL4 were separately digested with Pst I. These digests were combined in a ligation reaction, using T4 DNA ligase. The resulting mixture was used to transform the cells of strain SA291. Colonies were selected for a combination of growth in the absence of biotin and growth in the presence of 12 mg/mL tetracycline. Presence of the complete bio operon was confirmed by retransformation of plasmid-free SA291 in conjunction with restriction endonuclease digestion analysis.
- a resulting plasmid, designated pBP5 contained all of the genes of the biotin operon: genes bio A, bio B, bio F, bio C and the portion of the bio D gene upstream of the Pst I site derived from 322PstI and the portion of the bio D gene downstream of the Pst I site derived from pBAL4.
- Plasmid pCFM526 had been constructed as described in Morris, published European Patent Application No. 136,490, from plasmid pCFM414 (ATCC No. 40,076).
- plasmid pCFM526 ⁇ E4 and the plasmid pBP5 were separately digested with Hind III. The fragments were ligated and used to transform SA291. Colonies were selected for ampicillin resistance and the ability to grow in the absence of biotin. A plasmid designated pKA5 was isolated. This plasmid contained the five genes of the bio operon linked to a temperature inducible origin of replication.
- plasmid was also constructed in a fashion analogous to the construction of pKA5 described in Example 1, but with the substitution of a plasmid designated pCFM1036NS, which contains a kanamycin resistance segment, for pCFM526 ⁇ E4. Colonies were therefore selected for kanamycin resistance instead of ampicillin resistance to obtain cells bearing a plasmid pKH4.
- a Hind III fragment from pBP5 was treated with BAL 31 and the mixture was ligated into Hpa I-cut pCFM526 ⁇ E4. Colonies were selected for biotin production, ampicillin resistance, and tetracycline sensitivity. Three plasmids, pBA2, pBA4 and pBA6 were obtained from this selection.
- the plasmids pBP5 and pCFM526 were cut with Nco I and Hind III.
- the ligation product of these digests was transformed into an E. coli strain AM7 containing plasmid pMW1 (A.T.C.C. No. 39933) harboring a gene for the temperature sensitive repressor CI857.
- pBF1 the bio B gene is placed under the control of the P L promoter. Therefore, this construction is useful for converting desthiobiotin into biotin by means of the bio B gene product, biotin synthetase.
- the plasmid pLC2523 was digested with Hind III and Nco I.
- the plasmid pCFM526 was similarly cut.
- a ligation product of these two digests designated pAHN203, was transformed into cells of a bacterial strain containing the temperature-sensitive repressor of bacteriophage ⁇ (CI857).
- the plasmid pCFM526 contains the P L promoter of bacteriophage ⁇ .
- a gene or genes inserted downstream from this locus are controlled by this promoter.
- the promoter activity is regulated by repressor CI857. Therefore, when the temperature is raised, the repressor function is eliminated, the promoter is activated and the desired gene products are expressed. See e.g., Morris, supra .
- the bio A gene is under P L control.
- the plasmid pAHN203 is combined with pBF1 to produce a plasmid which produces biotin under P L control.
- a high salt buffer comprising: 75mM NaCl; 50mM Tris-HCl, pH 7.6; 10mM MgCl2; and 5mM dithiothreitol.
- a medium salt buffer comprising: 37.5mM NaCl; 30mM Tris-HCl, pH 7.6; 10mM MgCl2; and 5mM dithiothreitol.
- a low salt buffer comprising: 10mM Tris-HCl, pH 7.6; 10mM MgCl2; 20mM KCl; and 5mM dithiothreitol.
- a ligase buffer comprising: 50mM Hepes, pH 7.5; 10mM MgCl2; 5mM dithiothreitol; and 0.4mM adenosine triphosphate.
- a polynucleotide kinase buffer comprising: 50mM Tris-HCl, pH 7.6; 10mM MgCl2; 1mM spermidine; 5mM dithiothreitol; and 0.1 mM ethylenediamine tetraacetic acid (EDTA).
- a BAL 31 nuclease buffer comprising 12mM CaCl2; 12mM MgCl2; 200mM NaCl; 20mM Tris-HCl, pH 8.0; and 1mM EDTA.
- the restriction enzymes Eco RI and Nco I were used in the high salt buffer and were obtained from New England Biolabs, Beverly, Massachusetts.
- the restriction enzymes Bgl II, Bam HI, Hind III and Pst I were used in medium salt buffer and were obtained from New England Biolabs, Beverly, Massachusetts.
- the restriction enzyme Hpa I was used in the low salt buffer.
- the DNA ligase was used in ligase buffer and was obtained from New England Biolabs, Beverly, Massachusetts.
- the nuclease BAL 31 was used in BAL 31 nuclease buffer and was obtained from Bethesda Research Laboratories, Gaithersburg, Maryland. Bovine serum albumin was also obtained from Bethesda Research Laboratories.
- Ampicillin, kanamycin sulfate, chloramphenicol and tetracycline were obtained from Sigma Chemical Company (Sigma). St. Louis, Missouri. Desthiobiotin was also obtained from Sigma Chemical Company. Biotin was obtained from either Sigma or from J. T. Baker Chemical Company, Phillipsburg, New Jersey. Strain BM4062 which has been deposited (August 23, 1985) with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland as A.T.C.C. 53238, had lesions in the bio R function and the bir A function. The bir A mutants were temperature sensitive in that they were viable at low temperatures ( -28°C.) but unable to grow at high temperatures ( -43°C).
- the biotin concentration was determined by "cross-feeding" SA291 cells with the biotin produced by the designated strain. Initially, SA291 was cultured overnight in GMH broth (9 g/L vitamin assay Casamino Acids (Difco, Detroit, Michigan); 4 g/L glucose;20 ⁇ g/L 1-histidine;40 ⁇ g/L thiamine; 1mM MgSO4; 6 g/L Na2HPO4; 3 g/L KH2PO4; 0.5 g/L NaCl; and 1 g/L NH4Cl) supplemented with 300 pM d-biotin (50 ml volume) at 37°C. The overnight culture was diluted 400 fold in GMH broth.
- GMH broth 9 g/L vitamin assay Casamino Acids (Difco, Detroit, Michigan); 4 g/L glucose;20 ⁇ g/L 1-histidine;40 ⁇ g/L thiamine; 1mM MgSO4; 6 g/L Na2
- the biotin concentration was determined by a biotin spectrophotometric assay derived from McCormick et al., Analytical Biochemistry , 34 , 226-236 (1970). Specifically, 100 microliters of sample were transferred to a test tube to which 900 microliters of water were added. Concentrated H2SO4 (5 microliters) was added to reduce the pH of the solution to less than 2. To the solution was added 1 mL of n-butanol and the resulting solution was vortexed for one minute and then centrifuged for one minute at 3200 rpm. The upper, butanol phase of the solution was then transferred to a 1.5 mL Eppendorf tube.
- Examples 6 and 7 were constructed by transforming an appropriate host strain with a plasmid derived from Examples 1 or 2 accordance with the procedures described by Hanahan, supra.
- the host strains and plasmids utilized are listed in Table II.
- the appropriate host bearing plasmids were cultured overnight in GMH broth. A 10 mL aliquot of the culture was added to 1000 ml. of GMH broth supplemented with 20 mL of 1% alanine, 20 mL of 1% methionine, 20 mL of 0.7% cysteine and appropriate antibiotic (final concentration of 50mg/L ampicillin was used when plasmid pKA5 was employed and 25 mg/L of kanamycin sulfate was used when plamid pKH4 was employed.
- the fermentation was performed in a New Brunswick Bio-Flo fermentor with the following features: 1) constant agitation at 600 rpm; 2) sprarging with air; 3) pH control between 6.8 and 7.2 by automatic addition of concentrated ammonia hydroxide; 4) temperature control and 5) a slow feed during the course of the fermentation. Dissolved oxygen and carbon dioxide evolution were not monitored.
- the feed consisted of: 12% glucose; 0.6% vitamin assay casamino acids, 35 ⁇ M magnesium sulfate, 0.2% alanine, 0.2% methionine, 0.12% cysteine, 7 ⁇ M sodium molybdate and half strength M9 minimal salts. The feed was initiated eight hours after innoculation at a continuous rate of 14 mL/hr.
- the temperature at the time of innoculation was 30°C.
- the optical density of the culture reached approximately 10
- the temperature was incrementally raised to 40°C.
- the biotin concentrations reported in Table II were determined 24 hours after innoculation using either the microbiological assay (Run Nos. 8, 9 and 10) or the spectrophotometric assay (Run Nos. 10 and 12).
- a flask containing 30 mL of GMH broth was inoculated with the volume of the six cultures listed in the Table IV above. The resulting cultures were incubated with shaking at 37°C. At 0 hr, 6 hr, 21 hr, 30 hr and 45 hr an aliquot was removed and filter sterilized. (A 2.5 mL aliquot was removed at 0 hr, while 1 mL aliquots were removed at the other time points). The sterilized samples were assayed in accordance with the microbiological assay previously described and the results are illustrated in Table V.
Landscapes
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (11)
- Système de production de biotine comprenant: un microorganisme ayant un génotype birA⁻ et de l'ADN plasmidique, dans ladite cellule, qui code pour au moins un produit génétique de l'opéron biotine ou pour un de ses homologues fonctionnels.
- Système selon la revendication 1, dans lequel ledit microorganisme a un génotype birAts.
- Système selon la revendication 1 ou 2, dans lequel ledit ADN plasmidique code pour l'opéron biotine.
- Système selon la revendication 3, dans lequel ledit microorganisme a un génotype bioR⁻.
- Système selon la revendication 3, dans lequel ledit microorganisme a un génotype bio⁻.
- Système selon l'une quelconque des revendications 1 à 5, dans lequel ledit ADN plasmidique est uvrB⁻.
- Système selon l'une quelconque des revendications 1 à 6, dans lequel ledit ADN plasmidique code pour la biotine synthétase ou pour un de ses homologues fonctionnels.
- Système pour la production de biotine, comprenant: un microorganisme ayant un génotype (bio⁻, birA⁻, bioR⁻); et un ADN plasmidique, dans ladite cellule, dans lequel ledit ADN plasmidique code pour l'opéron biotine et dans lequel ledit ADN plasmidique est uvrB⁻.
- Système pour la production de biotine, comprenant: un microorganisme ayant un génotype (bio⁻, birAts, bioR⁻); et un ADN plasmidique, dans lesdites cellules, dans lequel ledit ADN plasmidique code pour l'opéron biotine et dans lequel ledit ADN plasmidique est uvrB⁻.
- Méthode de production renforcée de biotine, qui comprend la transformation d'un microorganisme ayant un génotype birA⁻ avec un ADN plasmidique codant pour un produit génétique de l'opéron biotine ou pour un de ses homologues fonctionnels.
- Méthode de conversion de desthiobiotine en biotine, qui comprend les étapes selon lesquelles on cultive un microorganisme hôte ayant un génotype birA⁻ et ayant de l'ADN plasmidique codant pour un produit du gène bioB de l'opéron biotine ou pour un de ses homologues fonctionnels, dans un milieu contenant de la desthiobiotine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT86905574T ATE87975T1 (de) | 1985-08-26 | 1986-08-26 | Herstellungsverfahren fuer biotin. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76984985A | 1985-08-26 | 1985-08-26 | |
US769849 | 1985-08-26 | ||
US89304286A | 1986-08-12 | 1986-08-12 | |
US893042 | 1986-08-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0236429A1 EP0236429A1 (fr) | 1987-09-16 |
EP0236429A4 EP0236429A4 (fr) | 1988-02-03 |
EP0236429B1 true EP0236429B1 (fr) | 1993-04-07 |
Family
ID=27118229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86905574A Expired - Lifetime EP0236429B1 (fr) | 1985-08-26 | 1986-08-26 | Systeme de synthese de la biotine |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0236429B1 (fr) |
KR (1) | KR880700072A (fr) |
AT (1) | ATE87975T1 (fr) |
AU (1) | AU599046B2 (fr) |
CA (1) | CA1317245C (fr) |
DE (1) | DE3688248T2 (fr) |
DK (1) | DK173842B1 (fr) |
ES (1) | ES2001398A6 (fr) |
FI (1) | FI93657C (fr) |
GR (1) | GR862197B (fr) |
IL (1) | IL79834A (fr) |
NO (1) | NO177756C (fr) |
NZ (1) | NZ217336A (fr) |
PT (1) | PT83256B (fr) |
WO (1) | WO1987001391A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3786578T2 (de) * | 1986-03-25 | 1994-02-03 | Nippon Zeon Co | Biotin-Synthetase kodierendes Gen und dessen Verwendung. |
AU616380B2 (en) * | 1986-09-30 | 1991-10-31 | Transgene S.A. | Cloning of the bioA, bioD, bioF, bioC, and bioH genes of Bacillus sphaericus, vectors and transformed cells and method for preparing biotin |
FR2604436B1 (fr) * | 1986-09-30 | 1989-07-21 | Transgene Sa | Clonage des genes bioa, biod, biof de bacillus sphaericus, vecteurs et cellules transformes et procede de preparation de la biotine |
FR2615514B2 (fr) * | 1987-05-18 | 1991-01-11 | Transgene Sa | Clonage des genes bioc et bioh de bacillus sphaericus, vecteurs et cellules transformees et procede de preparation de la biotine |
GB2216530B (en) * | 1988-03-22 | 1992-07-08 | Mini Agriculture & Fisheries | Genetic material for expression of biotin synthetase enzymes |
US5252466A (en) * | 1989-05-19 | 1993-10-12 | Biotechnology Research And Development Corporation | Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them |
FR2657622B1 (fr) * | 1990-01-31 | 1994-11-25 | Rhone Poulenc Sante | Polypeptides impliques dans la biosynthese des cobalamines et/ou des cobamides, sequences d'adn codant pour ces polypeptides, procede de preparation, et leur utilisation. |
DE4013522A1 (de) * | 1990-04-27 | 1991-10-31 | Bayer Ag | Verwendung von alkylcarbonsaeure-dimethylamiden als kristallisationsinhibitoren |
KR100250692B1 (ko) * | 1991-09-13 | 2000-04-01 | 후쿠하라 요시하루 | 바이오틴 오페론 |
JP2658716B2 (ja) * | 1992-01-24 | 1997-09-30 | 田辺製薬株式会社 | 新規微生物及びそれを用いるd−ビオチンの製法 |
ATE163198T1 (de) * | 1992-10-02 | 1998-02-15 | Lonza Ag | Biotechnologisches verfahren zur herstellung von biotin |
EP0635572A3 (fr) * | 1993-06-25 | 1995-03-08 | Hoffmann La Roche | Biosynthèse de biotine dans bacillus subtilis. |
US6361978B1 (en) | 1996-05-06 | 2002-03-26 | Roche Vitamins, Inc. | Production of biotin |
ATE281527T1 (de) | 1996-09-27 | 2004-11-15 | Dsm Ip Assets Bv | Biotin-biosynthese-gene ii |
DE19731274A1 (de) | 1997-07-22 | 1999-01-28 | Basf Ag | Verfahren zur Herstellung von Biotin |
US6432686B1 (en) | 1998-05-12 | 2002-08-13 | E. I. Du Pont De Nemours And Company | Method for the production of 1,3-propanediol by recombinant organisms comprising genes for vitamin B12 transport |
US7074608B1 (en) | 1998-05-12 | 2006-07-11 | E. I. Du Pont De Nemours And Company | Method for the production of 1,3-propanediol by recombinant organisms comprising genes for coenzyme B12 synthesis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56160998A (en) * | 1980-05-15 | 1981-12-11 | Nippon Zeon Co Ltd | Production of biotin active substance biotin vitamer |
JPS60996A (ja) * | 1983-06-18 | 1985-01-07 | 山田機械工業株式会社 | 折丁供給装置 |
-
1986
- 1986-08-22 CA CA000516630A patent/CA1317245C/fr not_active Expired - Fee Related
- 1986-08-22 NZ NZ217336A patent/NZ217336A/xx unknown
- 1986-08-25 GR GR862197A patent/GR862197B/el unknown
- 1986-08-25 IL IL79834A patent/IL79834A/xx not_active IP Right Cessation
- 1986-08-26 KR KR870700359A patent/KR880700072A/ko not_active Application Discontinuation
- 1986-08-26 DE DE8686905574T patent/DE3688248T2/de not_active Expired - Lifetime
- 1986-08-26 AU AU62297/86A patent/AU599046B2/en not_active Expired
- 1986-08-26 AT AT86905574T patent/ATE87975T1/de not_active IP Right Cessation
- 1986-08-26 ES ES8601369A patent/ES2001398A6/es not_active Expired
- 1986-08-26 EP EP86905574A patent/EP0236429B1/fr not_active Expired - Lifetime
- 1986-08-26 PT PT83256A patent/PT83256B/pt not_active IP Right Cessation
- 1986-08-26 WO PCT/US1986/001759 patent/WO1987001391A1/fr active IP Right Grant
-
1987
- 1987-04-15 DK DK198701974A patent/DK173842B1/da not_active IP Right Cessation
- 1987-04-16 FI FI871689A patent/FI93657C/fi not_active IP Right Cessation
- 1987-04-24 NO NO871723A patent/NO177756C/no not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
Ja 0.060.996, (NIPPON ZEON KK), 11 April 1983, Abstract * |
US 4 563 426, (YAMADA) 07 January 1986, Column 1, l. 58-68 * |
Also Published As
Publication number | Publication date |
---|---|
IL79834A (en) | 1992-08-18 |
ATE87975T1 (de) | 1993-04-15 |
GR862197B (en) | 1986-12-31 |
NZ217336A (en) | 1988-06-30 |
CA1317245C (fr) | 1993-05-04 |
FI871689A0 (fi) | 1987-04-16 |
PT83256A (en) | 1986-09-01 |
KR880700072A (ko) | 1988-02-15 |
NO871723L (no) | 1987-04-24 |
WO1987001391A1 (fr) | 1987-03-12 |
EP0236429A4 (fr) | 1988-02-03 |
DE3688248T2 (de) | 1993-07-15 |
NO177756C (no) | 1995-11-15 |
DK197487D0 (da) | 1987-04-15 |
PT83256B (pt) | 1988-07-01 |
DK173842B1 (da) | 2001-12-10 |
AU599046B2 (en) | 1990-07-12 |
ES2001398A6 (es) | 1988-05-16 |
AU6229786A (en) | 1987-03-24 |
NO871723D0 (no) | 1987-04-24 |
NO177756B (no) | 1995-08-07 |
FI871689A (fi) | 1987-04-16 |
EP0236429A1 (fr) | 1987-09-16 |
IL79834A0 (en) | 1986-11-30 |
DE3688248D1 (de) | 1993-05-13 |
FI93657B (fi) | 1995-01-31 |
FI93657C (fi) | 1995-05-10 |
DK197487A (da) | 1987-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0236429B1 (fr) | Systeme de synthese de la biotine | |
Laten et al. | Isopentenyladenosine deficient tRNA from an antisuppressor mutant of Saccharomyces cerevisiae | |
Escalante-Semerena et al. | cobA function is required for both de novo cobalamin biosynthesis and assimilation of exogenous corrinoids in Salmonella typhimurium | |
Frost et al. | Dehydroquinate synthetase from Escherichia coli: purification, cloning, and construction of overproducers of the enzyme | |
Ulrich et al. | Genetic and biochemical analyses of Escherichia coli mutants altered in the temperature-dependent regulation of membrane lipid composition | |
Horinouchi et al. | Construction and application of a promoter-probe plasmid that allows chromogenic identification in Streptomyces lividans | |
USRE34851E (en) | Biosynthesis of 2 keto-L-gulonic acid | |
KR20150127034A (ko) | 대사 공학을 통한 에르고티오네인 생성 | |
EP0057976B1 (fr) | Procédé pour cloner le gène codant pour une alpha-amylase thermostable dans escherichia coli et bacillus subtilis | |
CN114286858B (zh) | 叶酸生产菌株及其制备和应用 | |
Rizzino et al. | Derepressed levels of the isoleucine-valine and leucine enzymes in hisT1504, a strain of Salmonella typhimurium with altered leucine transfer ribonucleic acid | |
Hertzberg et al. | Cloning of an EcoRI-generated fragment of the leucine operon of Salmonella typhimurium | |
Grabau et al. | Molecular cloning of the gene (poxB) encoding the pyruvate oxidase of Escherichia coli, a lipid-activated enzyme | |
Grill et al. | Identification and characterization of two Streptomyces davawensis riboflavin biosynthesis gene clusters | |
US5110731A (en) | System for biotin synthesis | |
US4806480A (en) | Novel E. coli hybrid plasmid vector conferring sucrose fermenting capacity | |
Jeter et al. | Chromosomal location and function of genes affecting Pseudomonas aeruginosa nitrate assimilation | |
Li et al. | Inactivation of the monocistronic rca gene in Anabaena variabilis suggests a physiological ribulose bisphosphate carboxylase/oxygenase activase-like function in heterocystous cyanobacteria | |
EP2053128A1 (fr) | Procédé innovant d'utilisation d'un mutant microbien | |
JPH06225776A (ja) | リボフラビンの製造法 | |
JPS62155081A (ja) | 新規微生物およびそれを用いる醗酵法によるビオチンの製造法 | |
JPH022349A (ja) | ピリミジンアナログ耐性化遺伝子dnaおよびその用途 | |
Biel et al. | Mutations in the ilvY gene of Escherichia coli K-12 that cause constitutive expression of ilvC | |
Smith et al. | Characterization of fusions between the lac operon and the ilv gene cluster in Escherichia coli: ilvC-lac fusions | |
Saint-Girons et al. | Operator-constitutive mutants in the threonine operon of Escherichia coli K-12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19870814 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19880203 |
|
17Q | First examination report despatched |
Effective date: 19890418 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 87975 Country of ref document: AT Date of ref document: 19930415 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3688248 Country of ref document: DE Date of ref document: 19930513 |
|
ITF | It: translation for a ep patent filed | ||
ET | Fr: translation filed | ||
EPTA | Lu: last paid annual fee | ||
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
26 | Opposition filed |
Opponent name: SHISEIDO COMP. LTD. Effective date: 19940107 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: SHISEIDO COMP. LTD. |
|
EAL | Se: european patent in force in sweden |
Ref document number: 86905574.9 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: SHISEIDO COMP. LTD. Effective date: 19940107 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: SHISEIDO COMP. LTD. |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19970924 Year of fee payment: 12 |
|
PLBO | Opposition rejected |
Free format text: ORIGINAL CODE: EPIDOS REJO |
|
PLBN | Opposition rejected |
Free format text: ORIGINAL CODE: 0009273 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION REJECTED |
|
27O | Opposition rejected |
Effective date: 19980208 |
|
NLR2 | Nl: decision of opposition | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980826 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: AMGEN TRANSFER- GENENCOR INTERNATIONAL, INC. |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
NLS | Nl: assignments of ep-patents |
Owner name: GENENCOR INTERNATIONAL, INC. |
|
BECA | Be: change of holder's address |
Free format text: 20000719 *GENENCOR INTERNATIONAL INC.:4 CAMBRIDGE PLACE 1870 SOUTH WINTON ROAD, ROCHESTER NEW YORK 14618 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: GENENCOR INTERNATIONAL, INC. TRANSFER- ARCHER-DANI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20020802 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030827 |
|
EUG | Se: european patent has lapsed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20040803 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20040823 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20050729 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20050817 Year of fee payment: 20 Ref country code: GB Payment date: 20050817 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050826 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20050829 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20050902 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20050930 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20060825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20060826 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20060826 |
|
BE20 | Be: patent expired |
Owner name: *GENENCOR INTERNATIONAL INC. Effective date: 20060826 |